How Will Five Prime Therapeutics (NASDAQ:FPRX) Stock React To New Rating Coverage byWedbush?

May 18, 2018 - By Deanna Todd

Investors sentiment increased to 1.34 in Q4 2017. Its up 0.30, from 1.04 in 2017Q3. It increased, as 21 investors sold Five Prime Therapeutics, Inc. shares while 29 reduced holdings. 24 funds opened positions while 43 raised stakes. 25.47 million shares or 6.30% more from 23.96 million shares in 2017Q3 were reported.

Amundi Pioneer Asset Management holds 0.01% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX) or 202,800 shares. Blackrock invested in 0% or 2.20 million shares. Moreover, Public Employees Retirement Association Of Colorado has 0% invested in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Quantbot Tech Limited Partnership invested in 0% or 1,592 shares. Balyasny Asset Mgmt Ltd Liability Company reported 0.03% of its portfolio in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Sei owns 11 shares or 0% of their US portfolio. Td Asset Mngmt Inc invested 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Swiss Retail Bank holds 0% or 48,200 shares in its portfolio. Jacobs Levy Equity Mgmt owns 22,990 shares for 0.01% of their portfolio. Proshare Advsr Ltd Com invested in 0% or 19,623 shares. First Personal Fincl Services holds 0% or 226 shares. Winslow Evans Crocker Incorporated reported 0% in Five Prime Therapeutics, Inc. (NASDAQ:FPRX). Granite Point Cap Mgmt Lp holds 80,000 shares or 0.17% of its portfolio. 70,667 were accumulated by Citigroup. Fmr Limited owns 4.34 million shares for 0.01% of their portfolio.

Why Has Wedbush Given Five Prime Therapeutics (NASDAQ:FPRX) a $17 Price Target

In an analyst note made public today, Wedbush analysts has initiated Five Prime Therapeutics (NASDAQ:FPRX) coverage with “Neutral” rating, and a $17 PT.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Ratings Coverage

Among 5 analysts covering Five Prime Therapeutics (NASDAQ:FPRX), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Five Prime Therapeutics has $60 highest and $20 lowest target. $35’s average target is 85.19% above currents $18.9 stock price. Five Prime Therapeutics had 5 analyst reports since February 15, 2018 according to SRatingsIntel. The company was maintained on Thursday, March 1 by Jefferies. Guggenheim maintained it with “Buy” rating and $30.0 target in Thursday, February 15 report. BMO Capital Markets maintained Five Prime Therapeutics, Inc. (NASDAQ:FPRX) on Wednesday, February 28 with “Outperform” rating. The firm has “Buy” rating given on Wednesday, February 28 by Nomura.

The stock increased 0.80% or $0.15 during the last trading session, reaching $18.9. About 601,531 shares traded or 14.63% up from the average. Five Prime Therapeutics, Inc. (NASDAQ:FPRX) has declined 52.34% since May 18, 2017 and is downtrending. It has underperformed by 63.89% the S&P500.

Analysts await Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to report earnings on August, 14. They expect $-1.33 earnings per share, up 15.82 % or $0.25 from last year’s $-1.58 per share. After $-0.63 actual earnings per share reported by Five Prime Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 111.11 % negative EPS growth.

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics in the United States. The company has market cap of $665.46 million. The companyÂ’s product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor, as well as conducts Phase I clinical trials for the treatment of rheumatoid arthritis. It currently has negative earnings. The Company’s product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor IIb and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039, a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors.

More news for Five Prime Therapeutics, Inc. (NASDAQ:FPRX) were recently published by:, which released: “Five Prime Therapeutics’ (FPRX) CEO Aron Knickerbocker on Q1 2018 Results – Earnings Call Transcript” on May 13, 2018.‘s article titled: “Goldman Sachs Starts Five Prime Therapeutics (FPRX) at Neutral” and published on May 10, 2018 is yet another important article.

Five Prime Therapeutics, Inc. (NASDAQ:FPRX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: